New Risk • Apr 03
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.1b market cap, or US$28.6m). New Risk • Mar 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.2b market cap, or US$28.7m). Annuncio • Mar 17
Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026 Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Korea Annuncio • Feb 27
Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion. Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,556,759
Price\Range: KRW 1753
Transaction Features: Subsequent Direct Listing Annuncio • Dec 31
Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners Limited On December 30, 2025, Hyper Corporation Inc. closed the transaction. New Risk • Nov 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$28.1m). Annuncio • Sep 17
Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion. Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion on September 15, 2025. As part of the acquisition, Bestand Korea will acquire 0.021 shares AI Mindbot Equity. The consideration of KRW 8.5 billion will be paid in cash, out of which approximately KRW 850 million is paid as deposit on September 15, 2025 and the remaining KRW 7.6 billion will be paid upon completion of the acquisition. The transaction will be financed through Cash on hand and money borrowing. The expected completion of the transaction is November 7, 2025. New Risk • Aug 30
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩58.4b market cap, or US$42.1m). Annuncio • Aug 08
An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion. An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion on August 7, 2025. A cash consideration of KRW 2.8 billion will be paid by the buyer. As part of consideration, KRW 2.8 billion is paid towards common equity of Makeus Co.,Ltd.
The expected completion of the transaction is December 31, 2025. Board Change • Jun 26
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Mar 18
Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025 Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South Korea New Risk • Feb 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩73.2b market cap, or US$50.3m). New Risk • May 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩126.6b market cap, or US$92.7m). Annuncio • Apr 27
Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd. On April 26, 2024, Medifron DBT Co., Ltd. closed the transaction. Annuncio • Feb 17
Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in funding Medifron DBT Co., Ltd. announces private placement of 41,420,118 shares at an issue price of KRW 1,014 for a gross proceeds of KRW 41,999,999,652 on February 15, 2024. The transaction is expected to close on April 30, 2024. The transaction has been approved by the board of the company. Annuncio • Feb 16
Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd. Medifron DBT Co., Ltd. announced a private placement of 20,710,059 common shares at a price of KRW 1,014 per share for the gross proceeds of KRW 20,999,999,826 on February 15, 2024. The transaction will include participation from new investor FSN Co., Ltd. The transaction has ben approved by the shareholders of the company is expected to close on April 26, 2024. The shares are restricted to a hold period of 1 year. New Risk • Feb 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Market cap is less than US$100m (₩75.0b market cap, or US$56.4m). New Risk • Jul 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₩85.5b market cap, or US$66.3m). Annuncio • Dec 15
Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,Ltd On December 14, 2022, Medifron DBT Co., Ltd. closed the transaction. The company issued 3,427,600 shares in the transaction. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Aug 26
Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in funding On August 24, 2022, Medifron DBT Co., Ltd. closed the transaction. Annuncio • Aug 24
Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in funding Medifron DBT Co., Ltd. announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 3,000,000,000 on August 22, 2022. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on August 24, 2027. The bonds are 100% convertible into 1,784,651 common shares of the company representing 3.93% stake, at a fixed conversion price of KRW 1,681 per share from August 24, 2023 till July 24, 2027. The subscription and payment date for the bonds is August 24, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Mar 08
New 90-day low: ₩3,480 The company is down 17% from its price of ₩4,200 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 19% over the same period. Annuncio • Feb 06
Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd. On February 5, 2021, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction. Is New 90 Day High Low • Jan 28
New 90-day low: ₩3,620 The company is down 10.0% from its price of ₩4,030 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period. Is New 90 Day High Low • Dec 18
New 90-day low: ₩3,985 The company is down 20% from its price of ₩5,010 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 14% over the same period. Annuncio • Dec 02
Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in funding Medifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company. Is New 90 Day High Low • Oct 19
New 90-day low: ₩4,460 The company is down 7.0% from its price of ₩4,810 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 6.0% over the same period. Annuncio • Sep 03
Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment Corporation On September 1, 2020, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction. Annuncio • Aug 26
Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment Corporation Medifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 8 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on August 25, 2020. The transaction will include participation from new investor T.S. 2018-12 M&A Investment Fund, a fund managed by returning investor T.S. Investment Corporation (KOSDAQ:A246690). The bonds carry 0% coupon rate, 0% yield to maturity, will mature on September 01, 2025, and are 100% convertible into 3,998,400 common shares of the company representing 10.75% stake, at a fixed conversion price of KRW 5,002 per share from September 01, 2021 till August 01, 2025. The payment date for the bonds is September 01, 2020. The transaction has been approved by the board of directors of the company. 
